• Phase 2 study did not meet its primary endpoint.
  • Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy.
  • Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months.

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has decided not to advance the program in this indication as a topical eye drop.